Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MG-K10 in moderate-to-severe atopic dermatitis
CTR20252129Phase 2Completed
- Sponsor
- Medigene AG
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of comekibart in atopic dermatitis (AD), sponsored by Medigene AG. Started Jun 2025; status: completed.
02
Drugs
comekibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20252129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252129.